After some digging I have reason to believe that a formal partnership between ACTC and Wake Forests Dept. of Regenerative Medicine will be announced soon. ACTC would not only being a key player in the arena of ESCs but stem cells derived from amniotic fluid as well thanks to a licensing agreement. I still have some additional light digging to do, which would serve as a confirmation, but that may be precluded by an announcment from company officials.
This would have a profound effect on the stock price!!!
Robert Lanza (VP of Research at ACT) has collaborated with Dr. Atala at Wake Forest for years (beginning when he was at Childrens Hospital in Boston); so it would not be a surprise.
This stock is easily moved by press releases and related stem cell news. Unfortunately, the quick sell offs indicate high speculation and less expectation of long-term potential. Hopefully the capital markets will not push it around too much before they can get a clinical trial and focused cell-based product going, either by themselves or in partnership with another company.